AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11242482
Drug: Modified sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified sham feeding a moderate-fat meal (38 g fat)
Trial: 23387822
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (intraarterial thrombolysis with recombinant tissue plasminogen activator [t‐PA], mechanical clot disruption or retrieval, or a combination of these approaches)
Trial: 18761238
Drug: Remifentanil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.5 microg/kg bolus, 0.05 microg/kg per min infusion)
Trial: 18761238
Drug: Fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1 microg/kg bolus, 0.5 microg/kg bolus doses)
Trial: 16471102
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg IV administered twice
Trial: 16471102
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg IV administered twice
Trial: 12939421
Drug: Donepezil 10
RxNorm normalized name: donepezil 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 10 mg/day (after 5 mg/day for the first 28 days)
Trial: 10481525
Drug: Immunofluorescence with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunofluorescence with MAC‐1, MAC‐31, NSE and anti‐Fucosyl‐GM1 (PF3) antibodies
Trial: 8784635
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment in the NG group
Trial: 8784635
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment in the G group
Trial: 1810999
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dibenzoylmethane derivative and physical agents
Trial: 1810999
Drug: Physical agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical agents
Trial: 6925982
Drug: Single intrapleural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intrapleural injection of BCG
Trial: 29777003
Drug: Aducanumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aducanumab (1 mg/kg)
Trial: 29777003
Drug: Aducanumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aducanumab (3 mg/kg)
Trial: 29777003
Drug: Aducanumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aducanumab (6 mg/kg)
Trial: 29777003
Drug: Aducanumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aducanumab (10 mg/kg)
Trial: 22476230
Drug: Candesartan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan treatment (+ thiazide diuretics)
Trial: 18410608
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of Talpha1 (1.6 mg subcutaneously, twice a week) and lamivudine (100 mg orally, daily) for 24 weeks
Trial: 18410608
Drug: Lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine monotherapy continuously
Trial: 18410608
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of Talpha1 and lamivudine
Trial: 12016348
Drug: Magnetic field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic field treatment
Trial: 12016348
Drug: Standard medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication (diclofenac and tizanidine)
Trial: 8830065
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 to 200 mg per day for 8 weeks)
Trial: 35196
Drug: Clobazam (10-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (10-60 mg daily)
Trial: 35196
Drug: Clobazam (49
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (49 mg daily)
Trial: 31216852
Drug: Palliative systemic
RxNorm normalized name: Various pain palliation radiopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative systemic therapy
Trial: 23242758
Drug: Bacterial lysate
RxNorm normalized name: Thermus thermophilus lysate
DrugBank: Thermus thermophilus lysate (DB11227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial lysate (Escherichia coli and Enterococcus faecalis), prophylactic treatment for 26 weeks
Trial: 15314546
Drug: Low-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose interleukin-2 (3 x 10(6) IU/m2/day) administered daily for 6 weeks with a weekly melanoma peptide vaccine.
Trial: 11332212
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of 1 mg gemeprost (group 2A, n: 17)
Trial: 9329410
Drug: Heparin (1
RxNorm normalized name: 2,3-o-Desulfated heparin (12000 da)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (1 unit per milliliter in umbilical catheter infusate)
Trial: 1640278
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin (control group)
Trial: 26174571
Drug: Non-splint multimodal
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-splint multimodal therapy plus stabilisation splint (NS+S)
Trial: 26174571
Drug: Non-splint multimodal
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-splint multimodal therapy (NS)
Trial: 19597412
Drug: Polyglucosamine (PG)
RxNorm normalized name: PG
DrugBank: 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (DB11331)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyglucosamine (PG) 2 g/day
Trial: 14572565
Drug: 6.5-h infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5-h infusion of gabexate (500 mg total)
Trial: 14572565
Drug: 13-h infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13-h infusion of gabexate (1 g total)
Trial: 10629468
Drug: 2-component acellular
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-component acellular pertussis vaccine (APV) composed of pertussis toxin and filamentous hemagglutinin
Trial: 10629468
Drug: Meningococcal vaccine
RxNorm normalized name: Meningococcal vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal vaccine (control)
Trial: 8959467
Drug: Ethanol (0.55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.55 g/kg of body weight)
Trial: 1326741
Drug: D x
RxNorm normalized name: Bind X Brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D x RRV vaccine (10^4 plaque-forming units/1-ml dose)
Trial: 1326741
Drug: DS 1
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS 1 x RRV vaccine (10^5 plaque-forming units/1-ml dose)
Trial: 4048752
Drug: Cefoperazone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone (2 g/d)
Trial: 4048752
Drug: Ampicillin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (6 g/d) + Tobramycin (3 to 4 mg/kg/d)
Trial: 29553834
Drug: 2% dill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% dill vaginal suppositories
Trial: 29553834
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg clotrimazole vaginal tablets
Trial: 20151971
Drug: UK-369,003 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK-369,003 (10, 25, 50 or 100 mg once a day for 12 weeks)
Trial: 16437657
Drug: 5‐ASA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐ASA (50 mg/kg/d) + omega‐3 FAs (3 g/d, EPA 400 mg/g, DHA 200 mg/g)
Trial: 16437657
Drug: 5‐ASA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐ASA (50 mg/kg/d) + olive oil placebo capsules
Trial: 1421640
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin sodium 1000 units/mL
Trial: 6399890
Drug: Oral frusemide/amiloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral frusemide/amiloride combination tablet (40 mg frusemide and 5 mg amiloride)
Trial: 6399890
Drug: Commercially-available 40
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially-available 40 mg frusemide tablets
Trial: 6399890
Drug: Commercially-available 5
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially-available 5 mg amiloride tablets
Trial: 31033190
Drug: Metoprolol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol treatment in PEAR-2 study
Trial: 31033190
Drug: Atenolol treatment
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol treatment in PEAR study
Trial: 22892323
Drug: ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10 mg/day + statin
Trial: 22892323
Drug: double-dose statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: double-dose statin
Trial: 11281486
Drug: Cefazolin 1
RxNorm normalized name: cefazolin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 1 g intravenously after induction of anesthesia (PA group)
Trial: 8338261
Drug: 35 ml
RxNorm normalized name: ethanol 0.35 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 ml of 1.5% lidocaine with 1 in 200,000 of adrenaline (Group A)
Trial: 8338261
Drug: 1 microgram.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microgram.kg‐1 of fentanyl with the same dose of lidocaine (Group B)
Trial: 3525976
Drug: Antazoline (Antistine)
DrugBank: Antazoline (DB08799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antazoline (Antistine) in addition to conventional immunosuppressive therapy (group A)
Trial: 3525976
Drug: Conventional immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunosuppressive therapy only (group B)
Trial: 31665935
Drug: Dexamethasone 0.7
RxNorm normalized name: dexamethasone 0.7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.7 mg implant
Trial: 22519919
Drug: Imeglimin 2000
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imeglimin 2000 mg once daily
Trial: 22519919
Drug: Imeglimin 500
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imeglimin 500 mg twice daily
Trial: 22519919
Drug: Imeglimin 1500
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imeglimin 1500 mg twice daily
Trial: 10619726
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific therapy for funguria
Trial: 10619726
Drug: Catheter removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter removal as the only treatment
Trial: 1300186
Drug: Early surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early surgical treatment of contractures (release of hip flexors, removal of iliotibial bands, lengthening of tendo Achilles bilaterally)
Trial: 29096686
Drug: No supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplementation for patients with normal vitamin D levels (≥50 nmol/L)
Trial: 18825439
Drug: Donepezil or
RxNorm normalized name: donepezil Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil or Vitamin E (exact dosage and duration not specified)
Trial: 12477583
Drug: Remifentanil (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (n = 1,229) 0.5 microg/kg/min for induction and tracheal intubation followed by an infusion rate of 0.25 microg/kg/min
Trial: 12477583
Drug: Fentanyl (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (n = 1,209) administered according to the anesthesiologist's usual practice
Trial: 1935150
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg iv or 800 mg iv over 20 mins, followed by three 800-mg doses rectally every 6 hrs)
Trial: 30948695
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) administered in the preoperative and intraoperative periods
Trial: 26148587
Drug: Oxitard capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxitard capsules (2 capsules twice daily for 3 months)
Trial: 26148587
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 3 months)
Trial: 21295833
Drug: eLH (equine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eLH (equine LH) administered intravenously every 12 h from the day the largest follicle reached 20 mm until a follicle reached >32 mm
Trial: 21295833
Drug: Saline (transitional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (transitional control) administered in the same manner as eLH
Trial: 21295833
Drug: hCG (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG (3000 IU) administered after a follicle reached >32 mm
Trial: 17665051
Drug: Valdecoxib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib (40 mg)
Trial: 26463567
Drug: Aspiration with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration with steroid injection (AS)
Trial: 23992241
Drug: Multidisciplinary depression
RxNorm normalized name: Nerve depressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary depression management program (including activating strategies, psychotherapy, and medication)
Trial: 23992241
Drug: Pharmacological depression
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological depression treatment
Trial: 20577017
Drug: Standard immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard immunosuppressive therapy (prednisolone and cyclophosphamide)
Trial: 10491487
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy with pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for 7 or 14 days
Trial: 9005796
Drug: Ofloxacin administered
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin administered intravenously during the first days of treatment, followed by oral use
Trial: 1820900
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg) alone
Trial: 1820900
Drug: Lansoprazole with
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole with antacids (aluminium and magnesium hydroxides)
Trial: 1820900
Drug: Lansoprazole administered
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole administered one hour after antacids
Trial: 7091770
Drug: Pentaerythritol Tetranitrate
RxNorm normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaerythritol Tetranitrate (Peritrate) 40 mg chew-and-swallow tablets
Trial: 30082141
Drug: Citalopram 4
RxNorm normalized name: citalopram 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 4 mg (low group)
Trial: 30082141
Drug: Citalopram 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 16 mg (high group)
Trial: 26787345
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion analgesia (ED) with 0.2% Ropivacaine
Trial: 23095007
Drug: estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estradiol valerate in combination with testosterone undecanoate
Trial: 17440526
Drug: Glutamine-supplemented HPN
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine-supplemented HPN (10 g of glutamine)
Trial: 25285531
Drug: Obatoclax 20
RxNorm normalized name: Obatoclax
DrugBank: Obatoclax (DB12191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obatoclax 20 mg/day (3 h × 3 d)
Trial: 25285531
Drug: Obatoclax 60
RxNorm normalized name: Obatoclax
DrugBank: Obatoclax (DB12191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obatoclax 60 mg/day (24 h × 3 d)
Trial: 22556172
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of omeprazole (OPZ), 40 mg single dose
Trial: 22556172
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of omeprazole (OPZ)
Trial: 15991879
Drug: Neodolpasse (fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neodolpasse (fixed-dose combination of orphenadrine and diclofenac)
Trial: 9016417
Drug: Warfarin prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin prescribed
Trial: 9016417
Drug: Warfarin judged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin judged appropriate
Trial: 9016417
Drug: Warfarin prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin prescribed to older patients
Trial: 1352024
Drug: Ondansetron 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.15 mg/kg + dexamethasone 20 mg
Trial: 1352024
Drug: Metoclopramide 3
RxNorm normalized name: metoclopramide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 3 mg/kg + dexamethasone + diphenhydramine 50 mg
Trial: 3848264
Drug: Kallikrein 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kallikrein 600 units daily for 3-6 months
Trial: 31051049
Drug: Medium lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium lithium concentration mineral water (171 µg L‐1)
Trial: 31051049
Drug: High lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High lithium concentration mineral water (1724 µg L‐1)
Trial: 31051049
Drug: Low lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low lithium concentration mineral water (1.7 µg L‐1)
Trial: 9630129
Drug: Internal medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal medicine
Trial: 3075649
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (chiropractic adjustments of the thoracic spine T1-T5)
Trial: 30509293
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump with flash glucose measurement (FGM) device
Trial: 22526685
Drug: Minocycline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline plus treatment as usual (TAU)
Trial: 22526685
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus treatment as usual (TAU)
Trial: 9842818
Drug: Bupivacaine 2.5
RxNorm normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2.5 mg (B)
Trial: 9842818
Drug: Fentanyl 25
RxNorm normalized name: FENTANYL 25MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 25 microg + Bupivacaine 2.5 mg (F + B)
Trial: 8077066
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral nicorandil (5, 10, 20, or 30 mg)
Trial: 2684380
Drug: Buspirone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (5 mg) administered BID, titrated to optimal dose
Trial: 2684380
Drug: Diazepam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (5 mg) administered BID, titrated to optimal dose
Trial: 1189985
Drug: Glycerol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol infusion
Trial: 1189985
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no glycerol infusion)
Trial: 25449994
Drug: Dolutegravir administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir administered 2 hours before calcium carbonate or ferrous fumarate, fasting
Trial: 23377194
Drug: drospirenone-ethinyl estradiol
RxNorm normalized name: drospirenone-ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drospirenone-ethinyl estradiol + metformin (M)
Trial: 8294627
Drug: Control (Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Standard medical therapy alone)
Trial: 3555040
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg orally every 12 hours for a mean duration of 9.6 days (six to 18 days)
Trial: 3555040
Drug: Cefotaxime 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 2.0 g intravenously every eight hours for a mean duration of 9.3 days (five to 14 days)
Trial: 22302665
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids applied with a squirt system
Trial: 22302665
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids applied with a nasal spray